---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-100256"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2023-09-13T23:59:59+00:00"
generated_at: "2026-06-10T19:14:50.103938+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# HOOKIPA CMO Schlienger resigns; Board member Dr. Peters named interim clinical lead

## Summary
- CMO Dr. Katia Schlienger resigns effective September 30, 2023 to pursue new opportunities.
- Board member Dr. Malte Peters, former MorphoSys R&D head, appointed Senior Clinical Advisor ad interim.
- CEO reaffirms focus on HB-200 randomized trial, HB-300 prostate program, and Roche/Gilead collaborations.

## SEC filing metadata
- accession: 0001104659-23-100256
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2023-09-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000110465923100256/0001104659-23-100256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000110465923100256/tm2325987d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-100256
- JSON: https://secwatch.observer/filing/0001104659-23-100256.json
- Plain text: https://secwatch.observer/filing/0001104659-23-100256.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.